Patents by Inventor Yuichiro Taira

Yuichiro Taira has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant obligate anaerobic Gram-positive bacteria
    Patent number: 10882912
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: January 5, 2021
    Assignee: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • RECOMBINANT OBLIGATE ANAEROBIC GRAM-POSITIVE BACTERIA
    Publication number: 20190169305
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Application
    Filed: February 19, 2019
    Publication date: June 6, 2019
    Applicant: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • Recombinant obligate anaerobic gram-positive bacteria
    Patent number: 10266601
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Grant
    Filed: December 24, 2014
    Date of Patent: April 23, 2019
    Assignee: TEIKYO HEISEI UNIVERSITY
    Inventors: Takeshi Nishikawa, Yuichiro Taira, Ikuko Taira, Isao Ishida
  • RECOMBINANT OBLIGATE ANAEROBIC GRAM-POSITIVE BACTERIA (As amended)
    Publication number: 20160326256
    Abstract: An object of the present invention is to effectively induce cancer cell apoptosis using the anti-TRAIL-R1 antibody(ies) and the anti-TRAIL-R2 antibody(ies) and to reduce the toxicity imposed on normal cells. The present invention relates to recombinant obligate anaerobic Gram-positive bacteria that include a nucleic acid encoding a fusion protein having 3 or more anti-TRAIL-R1 single-chain antibodies and/or 3 or more anti-TRAIL-R2 single-chain antibodies, in an expressible state.
    Type: Application
    Filed: December 24, 2014
    Publication date: November 10, 2016
    Inventors: Takeshi NISHIKAWA, Yuichiro TAIRA, Ikuko TAIRA, Isao ISHIDA
  • ANTITUMOUR AGENT, MARKER FOR TUMOUR DETECTION, AND ORAL VACCINE AGENT
    Publication number: 20150191706
    Abstract: An object of the present invention is to provide an antitumor agent and/or a marker fur tumor detection with low invasiveness, few side effects, and high target specificity. Through the use of a recombinant obligate anaerobic gram-positive bacterium as an active ingredient containing a nucleic acid encoding a secretory fusion protein comprising a signal peptide, a low-molecular-weight single-chain antibody, and a functional peptide, an antitumor agent that enables delivery of a functional peptide to a target cell and/or a marker for tumor detection that enables monitoring of therapeutic effects over time are provided.
    Type: Application
    Filed: July 12, 2013
    Publication date: July 9, 2015
    Inventors: Yuichiro Taira, Isao Ishida